Boston Scientific announced the close of its acquisition of Silk Road Medical, the company behind transcarotid artery revascularisation (TCAR).
“The integration of the TCAR platform into our portfolio means we can offer a treatment option for patients suffering from carotid artery disease that can reduce the risk of stroke and lead to improved patient outcomes,” said Cat Jennings, president of vascular peripheral interventions at Boston Scientific.
Boston Scientific revealed on 18 June that it had entered into a definitive agreement to acquire Silk Road.
